US Bio Company CEO and CFO Cash Out Stock Options Worth Billions

Martin Rothblatt, CEO of U.S. rare-disease treatment specialist United Therapeutics Corporation (Nasdaq: UTHR), and CFO James Edgmond exercised stock options in late April and sold part of their holdings on the open market, securing multi-billion-won proceeds. On April 27, Rothblatt sold approximately $5.4 million (about ₩7 billion) of shares under a pre-arranged Rule 10b5-1 trading plan. Edgmond, through two option exercises and essentially cashless sales on April 27 and April 30, realized roughly $5.7 million (also around ₩7 billion). After these transactions, Rothblatt still directly owns about 40,000 shares and retains additional indirect holdings via family trusts, while Edgmond continues to hold roughly 18,000 shares, ensuring management’s ongoing equity stake.

In its first-quarter 2026 financial report released May 6, United Therapeutics posted revenue of $781.5 million (approximately ₩1 trillion), a 2% year-over-year decline. The company concurrently unveiled a $2 billion share-repurchase program and a $1.5 billion accelerated buyback agreement.

On the product front, the U.S. Food and Drug Administration granted regenerative medicine advanced therapy (RMAT) designation to miroliverELAP, its liver-assist device. United Therapeutics is also advancing clinical data and scientific presentations across pulmonary arterial hypertension, fibrotic diseases, and organ-replacement technologies as it broadens its pipeline.

Founded in 1996 by Rothblatt to develop a pulmonary arterial hypertension therapy for his daughter, United Therapeutics is a Nasdaq-listed biotech company focused on orphan cardiopulmonary treatments and next-generation organ-manufacturing technologies, including 3D bioprinting and xenotransplantation. Operating as a public benefit corporation, its long-term strategy emphasizes expanding access to rare-disease therapies and increasing the supply of transplantable organs.